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Treatment of cancers in the abdominal cavity, such as peritoneal dissemination, is diﬃcult, but in principle intraperitoneal
administration of anticancer drugs is expected to be preferable to systemic administration. Taxane anticancer drugs are used
to treat gastric cancer patients with peritoneal dissemination. They are administered as micellar preparations, Taxol and Taxotere,
which consist of paclitaxel in Cremophor EL (crEL) and docetaxel in Polysorbate-80 (PS-80), respectively. In this paper we review
the disposition kinetics of taxane anticancer drugs after intraperitoneal administration in peritoneal dissemination patients and
animal models and also discuss the eﬀect of the surfactant vehicle on the behavior of taxanes.
1.Introduction
Taxane alkaloids, paclitaxel and docetaxel, are widely used
in the treatment of various cancers. Their anticancer activity
is related to stabilization of microtubule assembly, and they
cause mitotic arrest in the G2M phase of the cell cycle [1].
Paclitaxel and docetaxel have similar chemical and physical
characteristics, as shown in Figure 1, and are barely soluble
in various solvents. They are therefore used as micellar
preparations, Taxol and Taxotere, which consist of paclitaxel
in Cremophor EL (crEL) and docetaxel in Polysorbate-80
(PS-80), respectively (Figure 2).
Chemotherapy for patients with peritoneal dissemina-
tion has generally been unsatisfactory. Peritoneal cancer
occurs in about 10–15% of patients with gastric cancer
and in about 50–60% of relapsed cases after gastrectomy.
In general, however, treatment of the peritoneal cancer is
ineﬀective, and the 5-year survival rate is extremely low even
after multidisciplinary treatment, such as surgical resection,
radiotherapy, and chemotherapy. In most cases, anticancer
drugs have been given by systemic administration. But,
the peritoneal cavity acts as a sanctuary against systemic
chemotherapy because of the existence of a blood-peritoneal
barrier consisting of stromal tissue between mesothelial cells
and submesothelial blood capillaries [2]. Thus, inadequate
therapeutic eﬀects might be due at least in part to failure of
the drugs to reach abdominal cancerous tissues at suﬃcient
concentration to eradicate the cancer. The intraperitoneal
(i.p.) dosage route might be better than systemic administra-
tion for treatment of peritoneal dissemination, and it would
be expected to produce a higher drug concentration in the
abdominal cavity and to exhibit a lower systemic toxicity
compared with intravenous (i.v.) administration. Fushida et
al. [3, 4] and Yonemura et al. [5] tried the i.p. infusion
of taxane anticancer drugs in gastric cancer patients with
peritoneal dissemination and reported that the treatment
was more eﬀective, with fewer side eﬀects, than systemic
i.v. administration. Sugarbaker et al. [6]h a v er e v i e w e d
perioperative intraperitoneal chemotherapy; they noted that
the ratio of the area under the drug concentration-time
curve (AUC) in the peritoneal cavity and AUC in plasma
(AUCa/AUCp) was much larger for paclitaxel and docetaxel
than for other anticancer drugs, suggesting that taxanes may
be eﬀective when used in early postoperative intraperitoneal
chemotherapy, without severe systemic toxicity. Moreover,
i . p .d o c e t a x e la p p e a r e dt ob em o r ee ﬀective than pacli-
taxel on peritoneal dissemination. Here, we review the
disposition kinetics of taxanes after i.p. administration of
taxane preparations and discuss the relationship between
the pharmacokinetic characteristics and anticancer eﬀects of2 Gastroenterology Research and Practice
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Figure 1: Chemical structures of taxane anticancer drugs. Circles indicate the diﬀerences between docetaxel and paclitaxel.
taxanes, as well as the inﬂuence of the micellar surfactant
vehicles.
2.DispositionKinetics inPatients with
PeritonealCancers
We investigated changes of taxane concentration in the
abdominal cavity and peripheral blood after i.p. admin-
istration in advanced gastric cancer patients with peri-
toneal dissemination [7]. Taxol (120mg,180mg) or Taxotere
(60mg,80mg) was dissolved in 1L of physiological saline
(ﬁnal concentration of surfactant; crEL: 1.1–1.6% for Taxol,
PS-80: 0.15–0.2% for Taxotere). and the preparation was
infused into the peritoneal cavity of nine patients for 1h.
Blood and ascites samples were collected at designated time
intervals, and the concentrations of paclitaxel and docetaxel
weremeasuredusingamodiﬁcationofthehigh-performance
liquid chromatography method of Vergniol et al. [8]a n d
Loos et al. [9].
When Taxol (120 and 180mg) was intraperitoneally in-
fused at a volume of 1L for 1h, the maximum peritoneal
concentrationsofpaclitaxeljustaftertheinfusionwereabout
110 and 190μg/mL, respectively, and decreased to 16 and
19μg/mL, respectively, after 24h. The plasma concentration
reached maximum levels of 38 and 54ng/mL, respectively,
within 3h after the infusion and fell below the detection
limit (5ng/mL) after 24h. On the other hand, after 1h
infusion of Taxotere (60 and 80mg/L), the maximum peri-
toneal concentrations of docetaxel were 29 and 40μg/mL,
respectively. These concentrations were about a half of the
calculated initial concentration of docetaxel, suggesting that
thedrugwasdistributedtotheperitonealtissuesorelsewhere
during infusion. The peritoneal concentration was about 1
to 6μg/mL after 24h. The plasma concentration reached the
maximum levels of about 112 and 144ng/mL, respectively,
within 2h after the infusion, then decreased to 5 to 10% of
the maximum after 24h.
Calculation of the pharmacokinetic parameters in ascitic
ﬂuid indicated that the distribution volume (Vda) and the
clearance (CLa) of docetaxel were two to three times than
those of paclitaxel. Among the pharmacokinetic parameters
in plasma of these drugs, Vdp, and CLp of paclitaxel were
larger than those of docetaxel, but the AUCp,0 −25 of
docetaxeltendedtobelargerthanthatofpaclitaxel.Theratio
of AUC in ascitic ﬂuid and AUC in plasma (AUCa/AUCp)
was 500 to 1700 for paclitaxel and 50 to 100 for docetaxel
(Table 1).Similarly,ithasbeenreportedthattheAUCa/AUCp
of paclitaxel (about 1,000) [10, 11] was larger than that
of docetaxel (about 200) [12, 13] after i.p. infusion. These
results suggest that after infusion of taxane preparations into
the peritoneal cavity, docetaxel is more easily transferred to
peripheral blood vessels than paclitaxel. Namely, after i.p.
infusion of Taxol the peritoneal concentration of paclitaxelGastroenterology Research and Practice 3
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Figure 2: Chemical structures of the major components of Cremophor EL and Polysorbate-80.
Table 1: The values of AUC of paclitaxel and docetaxel in plasma and ascitic ﬂuid after an i.p. infusion of Taxol and Taxotere in patients with
peritoneal tumor [7].
AUCp AUCa Ratio of
(mg∗hr/L) (mg∗hr/L) AUCa/AUCp
Paclitaxel 120mg 2.57 ± 1.43 1,298 ± 238 505
180mg 1.30 ± 0.86 2,214 ± 128 1705
Docetaxel 60mg 6.65 ± 3.75 370 ± 87 56
80mg 2.27 ± 0.65 238 ± 24 105
The value of AUC was calculated from 0 to 25h including the period of the infusion administration.
Each value represents the mean ± SE of three patients.
∗Signiﬁcantly diﬀerent from Taxotere at P < 0.01.
was well maintained for a long time and permeation into
the systemic circulation was low, suggesting that paclitaxel
should be eﬀective against peritoneal cancers, and side
eﬀects, such as bone marrow depression, should be weak.
In the case of intraperitoneally administered Taxotere, the
concentrations of docetaxel in the peritoneal cavity and
peripheral plasma were above the cytotoxic concentration
(in vitro IC50:4 – 3 5n g / m L )[ 14], so this anticancer drug may
exhibit anticancer action against peritoneal cancers but may
also cause systemic side eﬀects.
3. DispositionKinetics inPeritoneal
Dissemination Tumor Model Animals
The rat ascites hepatoma cell line AH130 was established
as transplantable tumor by Yoshida [16]. This cell line is
maintained by i.p. passage at weekly intervals in female
Donryu rats and is widely used to prepare animal models
of peritoneal cancer dissemination. The pharmacokinetic
behavior of taxane anticancer drugs and the eﬀects of
their micellar formulation vehicles have been studied using4 Gastroenterology Research and Practice
Table 2: The values of AUC of paclitaxel and docetaxel in plasma and ascitic ﬂuid after an i.p. injection of Taxol and Taxotere into AH130
tumor-bearing rats [15].
ka AUCp AUCa Ratio of
(hr−1)( m g ∗hr/L) (mg∗hr/L) AUCa/AUCp
Paclitaxel 0.0424 ± 0.0011∗ 17.6 ± 5.8∗ 7,480 ± 255∗ 425
Docetaxel 0.325 ± 0.043 8.50 ± 3.27 1,300 ± 191 153
The value of AUC was calculated from 0 to 24 h after an i.p. administration of 40 mg/kg of each drug.
ka: the apparent ﬁrst-order absorption rate constant from the peritoneal cavity.
Each value represents the mean ± SD of three rats.
∗Signiﬁcantly diﬀerent from Taxotere at P < 0.01.
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Figure 3: Time courses of paclitaxel (circles) or docetaxel (trian-
gles) concentration in ascitic ﬂuid (closed symbols) and plasma
(open symbols) after an i.p. injection of 40mg/kg of Taxol or
Taxotere into AH130 tumor-bearing rats [15]. Each point with bar
represents the mean ± SD of three rats.
this model [15]. Four-week-old female Donryu rats were
inoculated with 2 × 106 AH130 cells into the peritoneal
c a v i t ya n du s e df o re x p e r i m e n t sa f t e r1t o2w e e k s ,f o l l o w i n g
anovernightfast.TaxolorTaxoterewasgivenbyi.p.injection
at a dose of 40mg/kg in a 20mL volume containing 0.2%
blue dextran as a volume marker; the resulting peritoneal
solutions contained 4.2%crEL for paclitacel and 1.5%PS-
80 for docetaxel, which are close to the concentrations used
in the case of i.v. injection of taxanes in the clinic. In the
case of i.v. injection, 5mg/kg of each drug in a volume of
200μL was administered by bolus injection into the tail vein.
After i.p. or i.v. administration of taxanes to the AH130-
bearing rats, the concentrations of drugs in ascitic ﬂuid,
free cancer cells, and plasma obtained from the jugular vein
were measured at designated time intervals. Solid cancers
in the peritoneal cavity were excised after the rats had been
killedbydecapitation,andthedrugswereextractedandtheir
concentrations were measured.
After i.p. administration of taxanes, the ascitic concen-
tration of paclitaxel decayed very slowly, whereas that of doc-
etaxel decreased rapidly. The plasma concentrations of both
drugs were very low, but that of paclitaxel increased until
4h and then remained at a plateau, while that of docetaxel
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Figure 4: Time courses of paclitaxel (circles) or docetaxel (tri-
angles) concentration in free tumor cells in the peritoneal cavity
after an i.p. injection of 40mg/kg of Taxol or Taxotere into AH130
tumor-bearing rats [15]. Each point with bar represents the mean
± SD of three rats.
reachedthemaximumat1.5handthendecreased(Figure 3).
The values of AUCp, 0–24h, and AUCa, 0–24h of paclitaxel
were signiﬁcantly larger, by about 2- and 6-fold, respectively,
than those of docetaxel, and the apparent ﬁrst-order absorp-
tionrateconstantfromtheperitonealcavity(ka)ofpaclitaxel
was extremely small (Table 2). The AUCa/AUCp ratio of
paclitaxel was much larger than that of docetaxel. These
results indicate that paclitaxel was retained at much higher
concentration than docetaxel in the peritoneal cavity after
i.p.administrationoftaxanepreparations,andthetransferof
paclitaxel into the systemic circulation was much lower than
that of docetaxel, in agreement with clinical ﬁndings [7, 10–
13]. Figure 4 shows the changes of taxane concentration in
free cancer cells in the peritoneal cavity after i.p. adminis-
tration of Taxol and Taxotere (each 40mg/kg). The concen-
tration of paclitaxel was very low after Taxol administration,
while that of docetaxel was high just after Taxotere admin-
istration and then decreased gradually in parallel with the
decay of the peritoneal concentration. On the other hand, at
1hafteri.p.administration,theconcentrationofpaclitaxelin
solid cancer tissue growing in the peritoneum (1.3 ± 0.2μg/g
tissue) was lower than that of docetaxel (4.1 ± 2.8μg/g
tissue). Figure 5 shows the apparent concentration ratio in
solidcancertissueversusplasma(Kp,app)1hafteri.p.ori.v.
administration. No marked diﬀerence was observed betweenGastroenterology Research and Practice 5
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Figure 5: Values of apparent solid tumor to plasma concen-
tration ratio (Kp, app) of paclitaxel and docetaxel 1h after an
i.p. (40mg/kg, open column) or i.v. (5mg/kg, closed column)
injection of Taxol and Taxotere into AH130 tumor-bearing rats
[15]. Each column with bar represents the mean ± SD of three rats.
∗Signiﬁcantly diﬀerent from docetaxel at P < 0.05.
the Kp,app values of these drugs after i.p. administration,
but after i.v. administration the Kp, app of paclitaxel was
signiﬁcantly smaller than that of docetaxel. These results
indicate that after i.p. administration of Taxol, paclitaxel was
retained at high concentration in the peritoneal cavity and
was not readily transferred into either the systemic circula-
tion or cancer cells and tissues. The distribution of paclitaxel
into cancer tissues was also low after i.v. administration.
Docetaxel was more extensively distributed into cancer
tissues than paclitaxel after administration via both routes.
Moreover, we found that i.p. administration of docetaxel
rather than i.v. injection was pharmacokinetically superior
in the treatment of peritoneal dissemination of cancer
in mice [17, 19]. Docetaxel (8mg/kg) was intravenously
or intraperitoneally injected into athymic nude mice with
peritonealdisseminationofMKN-45Phumangastriccancer,
and we measured the concentration changes in plasma,
ascitic ﬂuid, solid cancer tissue, and cancer cells suspended
in the peritoneal cavity (Figure 6). The drug concentration
in ascitic ﬂuid was about 100-fold higher after i.p. injection
than after i.v. injection, while the plasma concentrations
were rather similar. In suspended free cancer cells in the
peritoneal cavity, the drug concentration was much higher
in the i.p. group than in the i.v. group, in parallel with
the concentrations in ascites after drug injection via these
routes. In the case of i.v. injection, the drug appeared rapidly
in solid cancer tissue and then the concentration gradually
decreased, following the change in the plasma concentration,
but the apparent cancer tissue to plasma concentration
ratio (Kp,app) was maintained at about 3 to 8 for 8h,
as observed in the AH130-bearing rat model (Figure 5).
Docetaxel concentration in solid cancer was maintained at
a higher level from 2h to 8h after i.p. injection as compared
withthatafteri.v.injection. Ontheotherhand, thedocetaxel
concentrations in normal organs rapidly decreased up to
1h and then gradually decreased in the i.v. group, while
in the i.p. group the concentrations increased up to 2 or
4h after injection and then slowly decreased [17]. Namely,
docetaxel injected into the peritoneal cavity was transferred
rather slowly to the peripheral blood ﬂow; the ratio of
AUCp/AUCa after i.p. injection of docetaxel was 0.071, but
when i.v. injected, the drug passed comparatively easily
into the peritoneal cavity from the blood ﬂow; the ratio of
AUCa/AUCp after i.v. injection was 0.233 although it has
been reported the existence of a blood-peritoneal barrier
[2]. These results indicate that the i.p. injection of docetaxel
was considered to be advantageous as a treatment method
for peritoneal dissemination of cancers, oﬀering higher local
drug concentration and low systemic toxicity compared with
i.v. injection.
4. Inﬂuence of Surfactant Vehicles on
the Pharmacokinetic Behavior of Taxanes
Because paclitaxel and docetaxel have physicochemically
similar properties, the diﬀerence of distribution after admin-
istration of these drugs may be attributed largely to the
surfactant vehicles used to micellize and dissolve these drugs,
but not the properties of the drugs themselves. Taxane
anticancer drugs are commercially available as micellar
preparations, Taxol and Taxotere, which consist of paclitaxel
in crEL and docetaxel in PS-80, respectively. It has been
reported that surfactants increase cellular accumulation of
anticancerdrugs andmodulate the drug resistance ofcancers
expressing P-glycoprotein [20, 21]. On the other hand,
crEL has been reported to inhibit the intestinal absorption
and tissue permeability of paclitaxel [22–25]. However, P-
glycoprotein is an eﬄux transporter in both multidrug-
resistant cells and small intestinal epithelium cells, and
therefore if these surfactants only inhibit the function of
P-glycoprotein, drug accumulation should increase. This
apparent contradiction may be explained as follows. CrEL
increased the sensitivity of multidrug-resistant cells to
daunorubicin at concentrations over 0.1μL/mL (0.01%)
and completely reversed the resistance at 2.0μL/mL (0.2%)
[26, 27]. PS-80 has also been shown to be a multidrug
resistance modulator in vitro at concentrations between 0.2
and 0.3μL/mL (0.02–0.03%) [21, 28] but was ineﬀective in
vivo, because of its very rapid clearance [27, 29]. Then, we
examined the inﬂuence of crEL and PS-80 on the in vitro
uptake of taxanes into AH130 cells, which do not express P-
glycoprotein [30]. The intracellular uptake of docetaxel and
paclitaxel decreased with increasing vehicle concentration
(Figure 7). When these drugs were dissolved in 0.0125%
ethanol (ﬁnal concentration), the intracellular amounts of
these drugs were similar, but in the presence of surfactants
(at concentrations above 0.0125%) paclitaxel transport into
the cells was less than half that of docetaxel. CrEL and PS-
80 at concentrations above 0.5% both inhibited paclitaxel
entry into red blood cells, in a concentration-dependent
manner and with similar potency [18]. These results indicate
that both surfactants inhibit the plasma membrane perme-
ability at concentrations above 0.125%, although they can
modulate the P-glycoprotein-dependent drug transport at
lower concentrations. It is thought that the cell membrane6 Gastroenterology Research and Practice
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Figure 6: Time courses of docetaxel concentration in plasma, ascetic ﬂuid, solid cancer, and suspended free cancer cells after an i.v. or i.p.
injection of Taxotere in MKN-45P gastric cancer-bearing mice [17]. Taxotere (8mg/kg) was i.v. (open symbols) or i.p. (closed symbols)
injected into cancer-bearing mice on day 21 after i.p. inoculation of 107 MKN-45P gastric cancer cells. Each point with bar represents the
mean ± SD of three mice. ∗Signiﬁcantly diﬀerent from i.v. injection at P < 0.05.
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Figure 7: Eﬀects of surfactants on uptake of paclitaxel and docetaxel in AH130 cells. Cells were treated with 3μg/mL of docetaxel (DOC) or
paclitaxel (PAC) dissolved with 0.125% ethanol (0) or the indicated concentrations of crEL or PS-80 (PS) for 30min. The data at 0.0125%
concentration of these surfactants are taken from [15]. Each column with bar represents the mean ± SD of at least three experiments
performed in triplicate. ∗,∗∗Signiﬁcantly diﬀerent from docetaxel at P < 0.05 and 0.01, respectively.
permeability of taxanes is determined by the degree of
aﬃnity for, and the ease of dissociation from, surfactant
micelles [31]. Paclitaxel seems to be trapped in the surfactant
micelles more easily and binds to them more strongly than
docetaxel.
Next, we compared the inﬂuence of surfactants on the
in vivo pharmacokinetics of taxanes administered intraperi-
toneallytorats[18].Afterinjectionofpaclitaxelin4.2%crEL
into the peritoneal cavity, the permeation of paclitaxel into
the systemic circulation was very slow compared with thatGastroenterology Research and Practice 7
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Figure 8: Inﬂuence of PS-80 on the anticancer eﬀect of docetaxel (1mg/kg) in AH130 tumor-bearing rats. AH130 tumor-bearing rats were
intraperitoneally administered 1mg/kg of docetaxel in a volume of 20mL of 1.5% or 7.5% PS-80 on day 0. N = 6.
Table 3: Pharmacokinetic parameters of paclitaxel (PAC) and docetaxel (DOC) in plasma and ascitic ﬂuid after an i.p. administration of
drugs in crEL or PS-80 to nontumor rats [18].
ka AUCp AUCa Ratio of
(hr−1)( m g ∗hr/L) (mg∗hr/L) AUCp/AUCa
PAC in 4.2% crEL 0.019 ±0.0018∗ 18.4 ±3.3∗ 8,870 ± 790∗ 0.00207 ± 0.00029∗
DOC in 1.5% PS-80 0.394 ±0.021 6.93 ±1.32 1,170 ± 120 0.00592 ± 0.00153
DOC in 4.2% crEL 0.165 ±0.004 8.59 ±1.23 3,520 ± 110 0.00244 ± 0.00026
DOC in 7.5% PS-80 0.130 ±0.005 11.4 ±1.1 3,130 ± 320 0.00364 ± 0.00026
The value of AUC was calculated from 0 to 24h after an i.p. administration of 40mg/kg of each drug.
ka: the apparent ﬁrst-order absorption rate constant from the peritoneal cavity.
Each value represents the mean ± SD of three rats.
∗Signiﬁcantly diﬀerent from DOC in 1.5% PS-80 at P < 0.01.
of docetaxel in 1.5% PS-80. However, the permeation of
docetaxel from the peritoneal cavity to the peripheral blood
stream was markedly decreased by changing the surfactant
from 1.5% PS-80 to 4.2% crEL though it did not reach the
levelofpaclitaxelin4.2%crEL.vanTellingenetal.[29]noted
that PS-80 does not interfere with the disposition kinetics of
docetaxel. However, the peritoneal permeability of docetaxel
wasloweredbyincreasingtheconcentrationofPS-80to7.5%
(Table 3).
Thus, the disposition kinetics of paclitaxel is inﬂuenced
more strongly than that of docetaxel by micellar surfactants,
as the concentration is increased.
5. Inﬂuence of Surfactants on
the AnticancerEffect of Taxanes
Finally, we examined the inﬂuence of surfactants on the
anticancer eﬀect of docetaxel after i.p. administration to
AH130-bearing rats. The anticancer eﬀect of docetaxel
became less potent as the concentration of PS-80 was
increased (Figure 8). The surfactant not only decreased the
permeation of the taxane into the systemic circulation and
maintained a high concentration of the drugs in the peri-
toneal cavity (Table 2), but also inhibited the drug transport
into cancer cells, in a concentration-dependent manner,8 Gastroenterology Research and Practice
thereby reducing the anticancer eﬀect. Similarly, it is thought
that the anticancer eﬀect of paclitaxel is strongly inﬂuenced
by its vehicle, crEL, because the cell permeation of paclitaxel
is readily inhibited by surfactants. The antitumor potency of
Taxotere is known to be about 3 times that of Taxol. But, this
diﬀerence in the potency of these antitumor drugs may be
due largely to the diﬀerence in the kind and concentration
of micellar surfactants used. Moreover, it has been reported
that PS-80 is readily degraded by serum esterase [27, 29, 31],
while crEL is stable in the body [32]. Consequently, because
Taxotere readily releases docetaxel in the peritoneal cavity so
that it can rapidly permeate into the systemic circulation,
not only can docetaxel be directly transported into cancer
cells, but also the drug can be distributed to cancer cells
from the blood. This has been called the “sandwich eﬀect”
of Taxotere or the dual anticancer eﬀect of docetaxel [33].
Taxol, a paclitaxel formulation with crEL, hardly releases the
antitumor agent, so the distribution to tumors is small, and
the antitumor potency may be less than that of Taxotere.
6. Conclusion andPerspective
Though the chemical and physical properties of taxane anti-
cancer drugs, paclitaxel, and docetaxel are very similar, the
disposition kinetics of these drugs are markedly inﬂuenced
by their micellar surfactant vehicles after administration of
commercial preparations. To treat peritoneal dissemination
of cancers, i.p. administration seems logically preferable to
systemic administration. In fact, after i.p. administration of
commercialpreparationsdilutedwithphysiologicalsolution,
paclitaxel showed a much higher i.p. concentration and less
penetration into the systemic circulation than docetaxel.
Consequently, the anticancer eﬀect of paclitaxel appears
to be stronger than that of docetaxel. However, actually
the opposite is the case because the cell permeability of
paclitaxel is signiﬁcantly inhibited by surfactants. Taxol
is a micellar formulation of paclitaxel in crEL, of which
the content is much higher than in other crEL micellar
preparations [34]. Taxotere is a preparation of docetaxel
micellized with PS-80, which is rapidly degraded in the body
and readily releases the anticancer ingredient, as compared
with crEL. These characteristics seem to be the reasons why
the anticancer eﬀect of Taxotere is more potent than that
of Taxol. Moreover, because many drugs are solubilized in
a micellar surfactant vehicle, such as crEL, pharmacokinetic
and pharmacodynamic drug-drug interactions may occur
when hydrophobic drugs are administered in combination
with an injection preparation containing a surfactant vehicle
[35]. Further, a preparation not containing crEL is desirable
to avoid hypersensitivity reaction. Recently, Abraxane has
been developed as a novel crEL-free nanoparticle albumin-
bound paclitaxel preparation. Data on the disposition kinet-
ics of paclitaxel after i.p. administration of the preparation
have not yet been reported and would be of consider-
able interest. Furthermore, hyperthermic intraperitoneal
chemoperfusion (HIPEC) has been developed for treatment
for peritoneal cancers with a variety of anticancer agents.
It will also be important to study the pharmacokinetics
of anticancer drugs in HIPEC to ensure safe and eﬀective
treatment.
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